參考文獻 |
References
[1] C.Langston, “Managing Fluid and Electrolyte Disorders in Renal Failure,” Veterinary Clinics of North America - Small Animal Practice, vol. 38, no. 3. pp. 677–697, 2008.
[2] W.-C.Yang andS.-J.Hwang, “Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance.,” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, vol. 23, no. 12, pp. 3977–82, 2008.
[3] D. O. F.Ckd andN.Graded, “Chapter 1: Definition and classification of CKD,” Kidney International Supplements, vol. 3, no. 1, pp. 19–62, 2013.
[4] M. J.Sarnak, A. S.Levey, A. C.Schoolwerth, J.Coresh, B.Culleton, L. L.Hamm, P. A.McCullough, B. L.Kasiske, E.Kelepouris, M. J.Klag, P.Parfrey, M.Pfeffer, L.Raij, D. J.Spinosa, andP. W.Wilson, “Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention,” Circulation, vol. 108, no. 17. pp. 2154–2169, 2003.
[5] M.Mallappallil, E. A.Friedman, B. G.Delano, S. I.McFarlane, andM. O.Salifu, “Chronic kidney disease in the elderly: evaluation and management,” Clin Pract (Lond), vol. 11, no. 5, pp. 525–535, 2014.
[6] R.Hajhosseiny, K.Khavandi, andD. J.Goldsmith, “Cardiovascular disease in chronic kidney disease: Untying the Gordian knot,” International Journal of Clinical Practice, vol. 67, no. 1. pp. 14–31, 2013.
[7] F.Verbeke, W.VanBiesen, andR.Vanholder, “The role of collagen metabolism in CKD-associated arterial senescence: Underestimated and underappreciated,” Nephrology Dialysis Transplantation, vol. 26, no. 9, pp. 2726–2728, 2011.
[8] M.Yisireyili, H.Shimizu, S.Saito, A.Enomoto, F.Nishijima, andT.Niwa, “Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats,” Life Sciences, vol. 92, no. 24–26, pp. 1180–1185, 2013.
[9] J.Nemcsik, I.Kiss, andA.Tislér, “Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease.,” World journal of nephrology, vol. 1, no. 1, pp. 25–34, 2012.
[10] M.Cecelja andP.Chowienczyk, “Role of arterial stiffness in cardiovascular disease,” JRSM Cardiovascular Disease, vol. 1, no. 4, pp. 1–10, 2012.
[11] S. J. E.Veringa, P. W. B.Nanayakkara, F. J.vanIttersum, I. L.Vegting, C.vanGuldener, Y. M. S. P. M.terWee, andC. D. A.Stehouwer, “Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on arterial compliance and distensibility in patients with mild-to-moderate chronic kidney disease,” Clinical Nephrology, vol. 78, no. 10, pp. 263–272, 2012.
[12] S. C.vanDijk, A. W.Enneman, K. M. A.Swart, J. P.vanWijngaarden, A. C.Ham, E. M.Brouwer-Brolsma, N. L.van derZwaluw, H. J.Blom, E. J.Feskens, J. M.Geleijnse, N. M.vanSchoor, R. A. M.Dhonukshe-Rutten, R. T.deJongh, P.Lips, L. C. P. G. M.deGroot, A. G.Uitterlinden, Y. M.Smulders, A. H.van denMeiracker, F. U. S.Mattace Raso, andN.van derVelde, “Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial,” Journal of Hypertension, vol. 33, no. 9, pp. 1897–1906, 2015.
[13] C. H.Liang, C. Y.Yang, K. C.Lu, P.Chu, C. H.Chen, Y. S.Chang, A. P.O’Brien, M.Bloomer, andK. R.Chou, “Factors affecting peritoneal dialysis selection in Taiwanese patients with chronic kidney disease,” Int Nurs Rev, vol. 58, no. 4, pp. 463–469, 2011.
[14] G. A.Beathard, “The Treatment of Vascular Access Graft Dysfunction: A Nephrologist’s View And Experience,” Advances in Renal Replacement Therapy, vol. 1, no. 2, pp. 131–147, 1994.
[15] J.Bergan, G.Schmidt-Schonbein, S.PD, A. N.Nicolaides, M.Boisseau, andB.Eklof, “Chronic Venous Disease,” The New England Journal of Medicine, vol. 355, no. 5, pp. 488–98, 2006.
[16] M. J.Brescia, J. E.Cimino, K.Appel, andB. J.Hurwich, “Chronic Hemodialysis Using Venipuncture and a Surgically Created Arteriovenous Fistula,” New England Journal of Medicine, vol. 275, no. 20, pp. 1089–1092, 1966.
[17] D.Santoro, F.Benedetto, P.Mondello, N.Pipitò, D.Barillà, F.Spinelli, C. A.Ricciardi, V.Cernaro, andM.Buemi, “Vascular access for hemodialysis: Current perspectives,” International Journal of Nephrology and Renovascular Disease, vol. 7. pp. 281–294, 2014.
[18] A.Asif, P.Roy-Chaudhury, andG. A.Beathard, “Early arteriovenous fistula failure: a logical proposal for when and how to intervene.,” Clinical journal of the American Society of Nephrology : CJASN, vol. 1, no. 2. pp. 332–339, 2006.
[19] H. J. T.Huijbregts, M. L.Bots, C. H. A.Wittens, Y. C.Schrama, F. L.Moll, andP. J.Blankestijn, “Hemodialysis arteriovenous fistula patency revisited: Results of a prospective, multicenter initiative,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 3, pp. 714–719, 2008.
[20] J.Malik, M.Slavikova, J.Svobodova, andV.Tuka, “Regular ultrasonographic screening significantly prolongs patency of PTFE grafts,” Kidney International, vol. 67, no. 4, pp. 1554–1558, 2005.
[21] K.Valji, J. J.Bookstein, A. C.Roberts, andG. B.Davis, “Pharmacomechanical thrombolysis and angioplasty in the management of clotted hemodialysis grafts: early and late clinical results.,” Radiology, vol. 178, no. 1, pp. 243–247, 1991.
[22] M.Levi, T.Van DerPoll, andH. R.Büller, “Bidirectional relation between inflammation and coagulation,” Circulation, vol. 109, no. 22. pp. 2698–2704, 2004.
[23] A. Y.Kim, P. L.Walinsky, F. D.Kolodgie, C.Bian, J. L.Sperry, C. B.Deming, E. A.Peck, J. G.Shake, G. B.Ang, R. H.Sohn, C. T.Esmon, R.Virmani, R. S.Stuart, andJ. J.Rade, “Early loss of thrombomodulin expression impairs vein graft thromboresistance: Implications for vein graft failure,” Circulation Research, vol. 90, no. 2, pp. 205–212, 2002.
[24] E. M.Conway andR. D.Rosenberg, “Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells.,” Molecular and cellular biology, vol. 8, no. 12, pp. 5588–5592, 1988.
[25] C. J.Chang, Y. S.Ko, P. J.Ko, L. A.Hsu, C. F.Chen, C. W.Yang, T. S.Hsu, andJ. H. S.Pang, “Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity,” Kidney International, vol. 68, no. 3, pp. 1312–1319, 2005.
[26] T. C.Rothuizen, C.Wong, P. H. A.Quax, A. J.VanZonneveld, T. J.Rabelink, andJ. I.Rotmans, “Arteriovenous access failure: More than just intimal hyperplasia?,” Nephrology Dialysis Transplantation, vol. 28, no. 5, pp. 1085–1092, 2013.
[27] B. S.Dixon, “Why don’t fistulas mature?,” Kidney International, vol. 70, no. 8. pp. 1413–1422, 2006.
[28] B. C.Liu, L.Li, M.Gao, Y. L.Wang, andJ. R.Yu, “Microinflammation is involved in the dysfunction of arteriovenous fistula in patients with maintenance hemodialysis,” Chinese Medical Journal, vol. 121, no. 21, pp. 2157–2161, 2008.
[29] M. F.Weiss, V.Scivittaro, andJ. M.Anderson, “Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access,” Am J Kidney Dis, vol. 37, no. 5, pp. 970–980, 2001.
[30] P.Roy-Chaudhury, L. M.Spergel, A.Besarab, A.Asif, andP.Ravani, “Biology of arteriovenous fistula failure,” Journal of Nephrology, vol. 20, no. 2. pp. 150–163, 2007.
[31] J.-J.Chiu andS.Chien, “Effects of Disturbed Flow on Vascular Endothelium: Pathophysiological Basis and Clinical Perspectives,” Physiological Reviews, vol. 91, no. 1, pp. 327–387, 2011.
[32] J. J.Paszkowiak andA.Dardik, “Arterial wall shear stress: observations from the bench to the bedside,” Vascular and Endovascular Surgery, vol. 37, no. 1, pp. 47–57, 2003.
[33] A. M.Malek, G. H.Gibbons, V. J.Dzau, andS.Izumo, “Fluid shear stress differentially modulates expression of genes encoding basic fibroblast growth factor and platelet-derived growth factor B chain in vascular endothelium.,” The Journal of clinical investigation, vol. 92, no. 4, pp. 2013–21, 1993.
[34] J. J.Bergan, G. W.Schmid-Schonbein, P. D.Smith, A. N.Nicolaides, M. R.Boisseau, andB.Eklof, “Chronic venous disease,” N Engl J Med, vol. 355, no. 5, pp. 488–498, 2006.
[35] National Kidney Foundation, “Clinical Practice Guidelines for Vascular Access,” American Journal of Kidney Diseases, vol. 48, no. SUPPL. 1, pp. 487–8, 2006.
[36] F. T.Padberg, K. D.Calligaro, andA. N.Sidawy, “Complications of arteriovenous hemodialysis access: Recognition and management,” Journal of Vascular Surgery, vol. 48, no. 5 SUPPL., 2008.
[37] L.Turmel-Rodrigues, J.Pengloan, S.Baudin, D.Testou, M.Abaza, G.Dahdah, A.Mouton, andD.Blanchard, “Treatment of stenosis and thrombosis in haemodialysis fistulas and grafts by interventional radiology,” Nephrology Dialysis Transplantation, vol. 15, no. 12, pp. 2029–2036, 2000.
[38] S.Sivanesan, T.V.How, R. A.Black, andA.Bakran, “Flow patterns in the radiocephalic arteriovenous fistula: An in vitro study,” Journal of Biomechanics, vol. 32, no. 9, pp. 915–925, 1999.
[39] Y. S. J.Li, J. H.Haga, andS.Chien, “Molecular basis of the effects of shear stress on vascular endothelial cells,” Journal of Biomechanics, vol. 38, no. 10. pp. 1949–1971, 2005.
[40] K.DenChen, Y. S.Li, M.Kim, S.Li, S.Yuan, S.Chien, andJ. Y. J.Shyy, “Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc,” Journal of Biological Chemistry, vol. 274, no. 26, pp. 18393–18400, 1999.
[41] Y. S.Li, J. Y.Shyy, S.Li, J.Lee, B.Su, M.Karin, andS.Chien, “The Ras-JNK pathway is involved in shear-induced gene expression.,” Mol. Cell. Biol., vol. 16, no. 11, pp. 5947–5954, 1996.
[42] Y. J.Shyy, H. J.Hsieh, S.Usami, andS.Chien, “Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium.,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 11, pp. 4678–82, 1994.
[43] L. W.Kraiss, R. L.Geary, E. J. R.Mattsson, S.Vergel, Y. P. T.Au, andA. W.Clowes, “Acute reductions in blood flow and shear stress induce platelet-derived growth factor-a expression in baboon prosthetic grafts,” Circulation Research, vol. 79, no. 1, pp. 45–53, 1996.
[44] X. L.Chen, S. E.Varner, A. S.Rao, J. Y.Grey, S.Thomas, C. K.Cook, M. A.Wasserman, R. M.Medford, A. K.Jaiswal, andC.Kunsch, “Laminar flow induction of antioxidant response element-mediated genes in endothelial cells: A novel anti-inflammatory mechanism,” Journal of Biological Chemistry, vol. 278, no. 2, pp. 703–711, 2003.
[45] D.Pons, F. R.DeVries, P. J.Van DenElsen, B. T.Heijmans, P. H. A.Quax, andJ. W.Jukema, “Epigenetic histone acetylation modifiers in vascular remodelling: New targets for therapy in cardiovascular disease,” European Heart Journal, vol. 30, no. 3. pp. 266–277, 2009.
[46] S. G.Gray andT. J.Ekstrom, “The human histone deacetylase family,” Exp Cell Res, vol. 262, no. 2, pp. 75–83, 2001.
[47] A.Scognamiglio, A.Nebbioso, F.Manzo, S.Valente, A.Mai, andL.Altucci, “HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2,” Biochimica et Biophysica Acta - Molecular Cell Research, vol. 1783, no. 10, pp. 2030–2038, 2008.
[48] B.Zhou, A.Margariti, L.Zeng, andQ.Xu, “Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis,” Cardiovasc Res, vol. 90, no. 3, pp. 413–420, 2011.
[49] X.Kong, M.Fang, P.Li, F.Fang, andY.Xu, “HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells,” Journal of Molecular and Cellular Cardiology, vol. 46, no. 3, pp. 292–299, 2009.
[50] C.Urbich, L.Rössig, D.Kaluza, M.Potente, J. N.Boeckel, A.Knau, F.Diehl, J. G.Geng, W. K.Hofmann, A. M.Zeiher, andS.Dimmeler, “HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells,” Blood, vol. 113, no. 22, pp. 5669–5679, 2009.
[51] L.Zeng, Y.Zhang, S.Chien, X.Liu, andJ. Y. J.Shyy, “The Role of p53 Deacetylation in p21Waf1 Regulation by Laminar Flow,” Journal of Biological Chemistry, vol. 278, no. 27, pp. 24594–24599, 2003.
[52] A.Zampetaki, L.Zeng, A.Margariti, Q.Xiao, H.Li, Z.Zhang, A. E.Pepe, G.Wang, O.Habi, E.Defalco, G.Cockerill, J. C.Mason, Y.Hu, andQ.Xu, “Histone deacetylase 3 is critical in endothelial survival and atherosclerosis development in response to disturbed flow,” Circulation, vol. 121, no. 1, pp. 132–142, 2010.
[53] E.Seto andM.Yoshida, “Erasers of histone acetylation: The histone deacetylase enzymes,” Cold Spring Harbor Perspectives in Biology, vol. 6, no. 4, 2014.
[54] J.Tang, H.Yan, andS.Zhuang, “Histone deacetylases as targets for treatment of multiple diseases.,” Clinical science (London, England : 1979), vol. 124, no. 11, pp. 651–62, 2013.
[55] S.-H.Kang, Y. M.Seok, M.Song, H.-A.Lee, T.Kurz, andI.Kim, “Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.,” Molecular pharmacology, vol. 87, no. 5, pp. 782–91, 2015.
[56] J. L.Hannan, O.Kutlu, B. L.Stopak, X.Liu, F.Castiglione, P.Hedlund, A. L.Burnett, andT. J.Bivalacqua, “Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve-injured rats,” Journal of Sexual Medicine, vol. 11, no. 6, pp. 1442–1451, 2014.
[57] H. C. R.Grunze, “The effectiveness of anticonvulsants in psychiatric disorders,” Dialogues in Clinical Neuroscience, vol. 10, no. 1. pp. 77–89, 2008.
[58] D.-Y.Lee, C.-I.Lee, T.-E.Lin, S. H.Lim, J.Zhou, Y.-C.Tseng, S.Chien, andJ.-J.Chiu, “Role of histone deacetylases in transcription factor regulation and cell cycle modulation in endothelial cells in response to disturbed flow,” Proceedings of the National Academy of Sciences, vol. 109, no. 6, pp. 1967–1972, 2012.
[59] M. S.Lemson, J. H. M.Tordoir, M. J. A. P.Daemen, andP. J. E. H. M.Kitslaar, “Intimal hyperplasia in vascular grafts,” European Journal of Vascular and Endovascular Surgery, vol. 19, no. 4. pp. 336–350, 2000.
[60] S. D.Patel, M.Waltham, A.Wadoodi, K. G.Burnand, andA.Smith, “The role of endothelial cells and their progenitors in intimal hyperplasia,” Therapeutic Advances in Cardiovascular Disease, vol. 4, no. 2. pp. 129–141, 2010.
[61] B.Ene-Iordache andA.Remuzzi, “Disturbed flow in radial-cephalic arteriovenous fistulae for haemodialysis: Low and oscillating shear stress locates the sites of stenosis,” Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 358–368, 2012.
[62] C. D.Owens, N.Wake, J. M.Kim, D.Hentschel, M. S.Conte, andA.Schanzer, “Endothelial function predicts positive arterial-venous fistula remodeling in subjects with stage IV and V chronic kidney disease.,” The journal of vascular access, vol. 11, no. 4, pp. 329–334, 2011.
[63] L.Li, C. M.Terry, Y. T. E.Shiu, andA. K.Cheung, “Neointimal hyperplasia associated with synthetic hemodialysis grafts,” Kidney International, vol. 74, no. 10. pp. 1247–1261, 2008.
[64] U. M.Balaguru, L.Sundaresan, J.Manivannan, R.Majunathan, K.Mani, A.Swaminathan, S.Venkatesan, D.Kasiviswanathan, andS.Chatterjee, “Disturbed flow mediated modulation of shear forces on endothelial plane: A proposed model for studying endothelium around atherosclerotic plaques,” Scientific Reports, vol. 6, 2016.
[65] M.Moradzadeh, A.Tabarraei, andH. R.Sadeghnia, “The Role of Histone Deacetylase (HDAC) as a Biomarker in Cancer,” Journal of Molecular Biomarkers & Diagnosis, vol. 06, no. 04, 2015.
[66] M. Y.Ahn, J. H.Jung, Y. J.Na, andH. S.Kim, “A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells,” Gynecologic Oncology, vol. 108, no. 1, pp. 27–33, 2008.
[67] M.Haberland, R. L.Montgomery, andE. N.Olson, “The many roles of histone deacetylases in development and physiology: Implications for disease and therapy,” Nature Reviews Genetics, vol. 10, no. 1. pp. 32–42, 2009.
[68] Y.Jeong, R.Du, X.Zhu, S.Yin, J.Wang, H.Cui, W.Cao, andC. J.Lowenstein, “Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1,” Journal of Leukocyte Biology, vol. 95, no. 4, pp. 651–659, 2014.
[69] S.Song, S. W.Kang, andC.Choi, “Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1,” Cardiovascular Research, vol. 85, no. 1, pp. 241–249, 2010.
[70] W.Wang, C. H.Ha, B. S.Jhun, C.Wong, M. K.Jain, andZ. G.Jin, “Fluid shear stress stimulates phosphorylation-dependent nuclear export of HDAC5 and mediates expression of KLF2 and eNOS,” Blood, vol. 115, no. 14, pp. 2971–2979, 2010.
[71] Z.Lin, “Kruppel-Like Factor 2 (KLF2) Regulates Endothelial Thrombotic Function,” Circulation Research, vol. 96, no. 5, pp. e48–e57, 2005.
[72] M. A.Alaiti, G.Orasanu, D.Tugal, Y.Lu, andM. K.Jain, “Kruppel-like factors and vascular inflammation: Implications for atherosclerosis,” Current Atherosclerosis Reports, vol. 14, no. 5, pp. 438–449, 2012.
[73] P.Novodvorsky andT. J. A.Chico, “Chapter Seven - The Role of the Transcription Factor KLF2 in Vascular Development and Disease,” in Genetics of Cardiovascular Disease, vol. Volume 124, 2014, pp. 155–188.
[74] L.Nayak, Z.Lin, andM. K.Jain, “‘Go with the flow’: how Krüppel-like factor 2 regulates the vasoprotective effects of shear stress.,” Antioxidants & redox signaling, vol. 15, no. 5, pp. 1449–61, 2011.
[75] I.-S.Kwon, W.Wang, S.Xu, andZ.-G.Jin, “Histone deacetylase 5 interacts with Kruppel-like factor 2 and inhibits its transcriptional activity in endothelium.,” Cardiovascular research, vol. 104, no. 1, pp. 127–137, 2014.
[76] E.DiGiorgio, A.Clocchiatti, S.Piccinin, A.Sgorbissa, G.Viviani, P.Peruzzo, S.Romeo, S.Rossi, A. P.Dei Tos, R.Maestro, andC.Brancolini, “MEF2 is a converging hub for HDAC4 and PI3K/Akt-induced transformation.,” Molecular and cellular biology, no. September, 2013.
[77] R.Janardhanan, B.Yang, P.Vohra, B.Roy, S.Withers, S.Bhattacharya, J.Mandrekar, H.Kong, E. B.Leof, D.Mukhopadhyay, andS.Misra, “Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model,” Kidney International, vol. 84, no. 2, pp. 338–352, 2013.
[78] M.Righetti, G.Ferrario, P.Serbelloni, S.Milani, andA.Tommasi, “Some Old Drugs Improve Late Primary Patency Rate of Native Arteriovenous Fistulas in Hemodialysis Patients,” Annals of Vascular Surgery, vol. 23, no. 4, pp. 491–497, 2009.
[79] R.Pisoni, J.Barker-Finkel, andM.Allo, “Statin therapy is not associated with improved vascular access outcomes.,” Clinical journal of the American Society of Nephrology : CJASN, vol. 5, no. 8, pp. 1447–50, 2010.
[80] D. M.Herrington, E.Vittinghoff, F.Lin, J.Fong, F.Harris, D.Hunninghake, V.Bittner, H. G.Schrott, R. S.Blumenthal, andR.Levy, “Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS),” Circulation, vol. 105, no. 25, pp. 2962–2967, 2002.
[81] N.Birch, J.Fillaus, andM. C.Florescu, “The effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses,” Hemodialysis International, vol. 17, no. 4, pp. 586–593, 2013.
[82] B.Ene-Iordache, L.Cattaneo, G.Dubini, andA.Remuzzi, “Effect of anastomosis angle on the localization of disturbed flow in ‘side-to-end’ fistulae for haemodialysis access,” Nephrology Dialysis Transplantation, vol. 28, no. 4, pp. 997–1005, 2013.
[83] J. E.Hull, B.V.Balakin, B. M.Kellerman, andD. K.Wrolstad, “Computational fluid dynamic evaluation of the side-to-side anastomosis for arteriovenous fistula,” Journal of Vascular Surgery, vol. 58, no. 1, 2013.
[84] E.Rajabi-Jagahrgh, M. K.Krishnamoorthy, P.Roy-Chaudhury, P.Succop, Y.Wang, A.Choe, andR. K.Banerjee, “Longitudinal assessment of hemodynamic endpoints in predicting arteriovenous fistula maturation,” Seminars in Dialysis, vol. 26, no. 2, pp. 208–215, 2013.
[85] M.Mottamal, S.Zheng, T. L.Huang, andG.Wang, “Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents,” Molecules, vol. 20, no. 3. pp. 3898–3941, 2015.
[86] J. M.López-Novoa, A. B.Rodríguez-Peña, A.Ortiz, C.Martínez-Salgado, andF. J.López Hernández, “Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications,” Journal of Translational Medicine, vol. 9, no. 1, p. 13, 2011.
[87] J. P.Cardinale, S.Sriramula, R.Pariaut, A.Guggilam, N.Mariappan, C. M.Elks, andJ.Francis, “HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats,” Hypertension, vol. 56, no. 3, pp. 437–444, 2010.
[88] S.Khan, G.Jena, andK.Tikoo, “Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat,” Experimental and Molecular Pathology, vol. 98, no. 2, pp. 230–239, 2015.
[89] I.Mannaerts, N. R.Nuytten, V.Rogiers, K.Vanderkerken, L. avanGrunsven, andA.Geerts, “Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo.,” Hepatology (Baltimore, Md.), vol. 51, no. 2, pp. 603–14, 2010.
[90] G.Kang, Y. R.Lee, H. K.Joo, M. S.Park, C. S.Kim, S.Choi, andB. H.Jeon, “Trichostatin a modulates angiotensin II-induced vasoconstriction and blood pressure via inhibition of p66shc activation,” Korean Journal of Physiology and Pharmacology, vol. 19, no. 5, pp. 467–472, 2015.
[91] W.Lin, Q.Zhang, L.Liu, S.Yin, Z.Liu, andW.Cao, “Klotho restoration via acetylation of Peroxisome Proliferation–Activated Receptor γ reduces the progression of chronic kidney disease,” Kidney International, vol. 92, no. 3, pp. 669–679, 2017.
[92] A.Iyer, A.Fenning, J.Lim, G. T.Le, R. C.Reid, M. A.Halili, D. P.Fairlie, andL.Brown, “Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats: Research paper,” British Journal of Pharmacology, vol. 159, no. 7, pp. 1408–1417, 2010.
[93] J.Choi, S.Park, T. K.Kwon, S. I.Sohn, K. M.Park, andJ. I.Kim, “Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis,” International Journal of Obesity, vol. 41, no. 11, pp. 1702–1709, 2017.
[94] M.Pang, L.Ma, N.Liu, M.Ponnusamy, T. C.Zhao, H.Yan, andS.Zhuang, “Histone deacetylase 1/2 mediates proliferation of renal interstitial fibroblasts and expression of cell cycle proteins,” Journal of Cellular Biochemistry, vol. 112, no. 8, pp. 2138–2148, 2011.
[95] M.Pang andS.Zhuang, “Histone deacetylase: a potential therapeutic target for fibrotic disorders.,” The Journal of pharmacology and experimental therapeutics, vol. 335, no. 2, pp. 266–72, 2010.
[96] P.Soderland, S.Lovekar, D. E.Weiner, D. R.Brooks, andJ. S.Kaufman, “Chronic Kidney Disease Associated With Environmental Toxins and Exposures,” Advances in Chronic Kidney Disease, vol. 17, no. 3. pp. 254–264, 2010.
[97] R. X.Li, W. H.Yiu, andS. C. W.Tang, “Role of bone morphogenetic protein-7 in renal fibrosis,” Frontiers in Physiology, vol. 6, 2015.
[98] N.Liu, S.He, L.Ma, M.Ponnusamy, J.Tang, E.Tolbert, G.Bayliss, T. C.Zhao, H.Yan, andS.Zhuang, “Blocking the Class I Histone Deacetylase Ameliorates Renal Fibrosis and Inhibits Renal Fibroblast Activation via Modulating TGF-Beta and EGFR Signaling,” PLoS ONE, vol. 8, no. 1, 2013.
[99] K.VanBeneden, C.Geers, M.Pauwels, I.Mannaerts, D.Verbeelen, L. avanGrunsven, andC.Van denBranden, “Valproic acid attenuates proteinuria and kidney injury.,” Journal of the American Society of Nephrology : JASN, vol. 22, no. 10, pp. 1863–75, 2011.
[100] J. K.Ryu, W. J.Kim, M. J.Choi, J. M.Park, K. M.Song, M. H.Kwon, N. D.Das, K. D.Kwon, D.Batbold, G. N.Yin, andJ. K.Suh, “Inhibition of histone deacetylase 2 mitigates profibrotic TGF-??1 responses in fibroblasts derived from Peyronie’s plaque,” Asian Journal of Andrology, vol. 15, no. 5, pp. 640–645, 2013.
[101] S.Yoon andG. H.Eom, “HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases,” Chonnam Medical Journal, vol. 52, no. 1, p. 1, 2016.
[102] J. Z.Xinming Luo, Ming Zhang, Liying Deng, “Effects of valproate on the carotid artery intima-media thickness in epileptics,” Indian J Pharmacol, vol. 47, pp. 45–48, 2015.
[103] T.Azechi, D.Kanehira, T.Kobayashi, R.Sudo, A.Nishimura, F.Sato, andH.Wachi, “Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase.,” Journal of atherosclerosis and thrombosis, vol. 20, no. 6, pp. 538–547, 2013.
[104] X.-Y.Dai, M.-M.Zhao, Y.Cai, Q.-C.Guan, Y.Zhao, Y.Guan, W.Kong, W.-G.Zhu, M.-J.Xu, andX.Wang, “Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release,” Kidney International, vol. 83, no. 6, pp. 1042–1051, 2013.
[105] J. H.Choi, K. H.Nam, J.Kim, M. W.Baek, J. E.Park, H. Y.Park, H. J.Kwon, O. S.Kwon, D. Y.Kim, andG. T.Oh, “Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 11, pp. 2404–2409, 2005.
[106] Clin J Am Soc Nephrol. “New Insights into Dialysis Vascular Access: Molecular Targets in Arteriovenous Fistula and Arteriovenous Graft Failure and Their Potential to Improve Vascular Access Outcomes. ” Clinical Journal of the American Society of Nephrology, vol. 11, no. 8, pp. 1504-1512, 2016.
[107] Berardi DE1, Tarbell JM. “Stretch and Shear Interactions Affect Intercellular Junction Protein Expression and Turnover in Endothelial Cells. ” Cellular and Molecular Bioengineering, vol. 2, no. 3, pp. 320-331, 2009.
[108] Harikrishnan KN1, Karagiannis TC, Chow MZ, El-Osta A. “Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments. ” Cell Cycle, vol. 7, no. 4, pp. 468-476, 2008. |